Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/t-dxd-reduces-residual-disease-early-breast-cancer-2026a1000evn?src=rss
Author :
Publish date : 2026-05-08 11:45:00
Copyright for syndicated content belongs to the linked Source.